Effects of deferasirox on renal function and renal epithelial cell death

Toxicology Letters

Volumn 203, Issue 2, 2011, Pages 154-161

  Sánchez González, Penélope D ^a,b   López Hernandez, Francisco J ^a,b,c   Morales, Ana I ^a,b   Macías Nuñez, Juan F ^a,c   López Novoa, Jose M ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b Instituto Reina Sofia de Investigacion Nefrologica   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Deferasirox; Iron chelator; Iron overload; Rats; Renal toxicity; Tubular cell lines

Indexed keywords

ALBUMIN; CASPASE 3; CREATININE; DEFERASIROX; GLUCOSE; KIDNEY INJURY MOLECULE 1; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN; UREA;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DNA FRAGMENTATION; DRUG CYTOTOXICITY; ENZYME ACTIVITY; EPITHELIUM CELL; GLOMERULUS FILTRATION RATE; GLUCOSE URINE LEVEL; GLUCOSURIA; HEMATOCRIT; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY BLOOD FLOW; KIDNEY EPITHELIUM; KIDNEY FUNCTION; KIDNEY TUBULE NECROSIS; KIDNEY VASCULAR RESISTANCE; MALE; MICTURITION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; UREA BLOOD LEVEL; URINARY EXCRETION; URINE LEVEL;

ACETYLGLUCOSAMINIDASE; ANIMALS; APOPTOSIS; BENZOIC ACIDS; CELL ADHESION MOLECULES; CELL LINE; CHICK EMBRYO; CLUSTERIN; CYSTATIN C; EPITHELIAL CELLS; GLOMERULAR FILTRATION RATE; HISTOCYTOCHEMISTRY; IRON CHELATING AGENTS; KIDNEY; KIDNEY DISEASES; LIPOCALINS; MALE; RATS; RATS, WISTAR; TRIAZOLES;

RATTUS; RATTUS NORVEGICUS;

EID: 79955471156     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.03.018     Document Type: Article

References (37)

1. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988, 48:589-601.
2. Bonventre J.V. Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrol. Dial. Transplant. 2009, 24:3265-3268.
3. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 7(72):248-254.
4. Brosnahan G., Gokden N., Swaminathan S. Acute interstitial nephritis due to deferasirox: a case report. Nephrol. Dial. Transplant. 2008, 23:3356-3358.
5. Cappellini M.D., Cohen A., Piga A., et al. phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassaemia. Blood 2006, 107:3455-3462.
6. Cianciulli P., Sollecito D., Sorrentino F., et al. Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy. Kidney Int. 1994, 46:467-470.
7. Doonan F., Cotter T.G. Morphological assessment of apoptosis. Methods 2008, 44:200-204.
8. Economou M., Printza N., Teli A., Tzimouli V., Tsatra I., Papachristou F., Athanassiou-Metaxa M. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Haematol. 2010, 123:148-152.
9. Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998, 391:43-50.
10. Even-Or E., Becker-Cohen R., Miskin H. Deferasirox treatment may be associated with reversible renal Fanconi syndrome. Am. J. Hematol. 2010, 85:132-134.
11. Galanello R., Piga A., Forni G.L., et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in paediatric patients with beta-thalassaemia major. Haematologica 2006, 91:1343-1351.
12. Grange S., Bertrand D.M., Guerrot D., Eas F., Godin M. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol. Dial. Transplant. 2010, 25(7):2376-2378.
13. Ko G.J., Grigoryev D.N., Linfert D., Jang H.R., Watkins T., Cheadle C., Racusen L.C., Rabb H. Transcriptional analysis of kidneys during repair from AKI reveals possible roles for NGAL and KIM-1 as biomarkers of AKI to CKD transition. Am. J. Physiol. Renal Physiol. 2010, 298:F1472-F1483.
14. Liangos O., Perianayagam M.C., Vaidya V.S., Han W.K., Wald R., Tighiouart H., MacKinnon R.W., Li L., Balakrishnan V.S., Pereira B.J., Bonventre J.V., Jaber B.L. Urinary N-acetyl-beta-(d)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J. Am. Soc. Nephrol. 2007, 18(3):904-912.
15. López-Farré A., Gómez-Garre D.N., Bernabeu F., López-Novoa J.M. A role for endothelin in the maintenance of post-ischemic renal failure in the rat. J. Physiol. 1991, 444:513-522.
16. López-Farré A., Bernabeu F., Gómez-Garre D., Ramon y Cajal S., Braquet P., López-Novoa J.M. Platelet-activating factor antagonists treatment protects against postischemic acute renal failure in rats. J. Pharmacol. Exp. Ther. 1990, 253:328-333.
17. Lopez-Novoa J.M., Quiros Y., Vicente L., Morales A.I., Lopez-Hernandez F.J. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011, 79:33-45.
18. Mills J.C., Stone N.L., Pittman R.N. Extranuclear apoptosis. The role of the cytoplasm in the execution phase. J. Cell Biol. 1999, 146:703-708.
19. Morales A.I., Detaille D., Prieto M., Puente A., Briones E., Arévalo M., Leverve X., López-Novoa J.M., El-Mir M.Y. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. Kidney Int. 2010, 77:861-869.
20. Morales A.I., Vicente-Sanchez C., Jerkic M., Santiago J.M., Sanchez-Gonzalez P.D., Perez-Barriocanal F., Lopez-Novoa J.M. Effect of quercetin on metallothionein, nitric oxide synthases and cyclooxygenase-2 expression on experimental chronic cadmium nephrotoxicity in rats. Toxicol. Appl. Pharmacol. 2006, 210:128-135.
21. Norberg E., Orrenius S., Zhivotovsky B. Mitochondrial regulation of cell death: processing of apoptosis-inducing factor (AIF). Biochem. Biophys. Res. Commun. 2010, 396:95-100.
22. Ortiz M.A., Lopez-Hernandez F.J., Bayon Y., Pfahl M., Piedrafita F.J. Retinoid-related molecules induce cytochrome c release and apoptosis through activation of c-Jun NH(2)-terminal kinase/p38 mitogen-activated protein kinases. Cancer Res. 2001, 61:8504-8512.
23. Papadopoulos N., Vasiliki A., Aloizos G., Tapinis P., Kikilas A. Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. Ann. Pharmacother. 2010, 44:219-221.
24. Piga A., Galanello R., Forni G.L., et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassaemia patients with transfusional iron overload. Haematologica 2006, 91:873-880.
25. Rafat C., Fakhouri F., Ribeil J., et al. Fanconi syndrome due to deferasirox. Am. J. Kidney Dis. 2009, 54:931-934.
26. Rodriguez-Barbero A., Bosque E., Rivas-Cabaero L., Arévalo M., López-Novoa J.M. Effect of platelet activating factor antagonist treatment on gentamicin nephrotoxicity. Mediators Inflammat. 1992, 1:23-26.
27. Ryan M.J., Johnson G., Kirk J., Fuerstenberg S.M., Zager R.A., Torok-Storb B. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int. 1994, 45:48-57.
28. Salvesen G.S. Caspases and apoptosis. Essays Biochem. 2002, 38:9-19.
29. Soni S.S., Cruz D., Bobek I., Chionh C.Y., Nalesso F., Lentini P., de Cal M., Corradi V., Virzi G., Ronco C. NGAL: a biomarker of acute kidney injury and other systemic conditions. Int. Urol. Nephrol. 2010, 42:141-150.
30. Stumpf J.L. Deferasirox. Am. J. Health Syst. Pharm. 2007, 64:606-616.
31. Trof R.J., Di Maggio F., Leemreis J., Groeneveld A.B., Shock Biomarkers of acute renal injury and renal failure. Shock 2006, 26:245-253.
32. VanOrden H.E., Hagemann T.M. Deferasirox-An oral agent for chronic iron overload. Ann. Pharmacother. 2006, 40:1110-1117.
33. Vichinsky E. Clinical application of deferasirox: practical patient management. Am. J. Hematol. 2008, 83:398-402.
34. Waanders F., van Timmeren M.M., Stegeman C.A., Bakker S.J., van Goor H. Kidney injury molecule-1 in renal disease. J. Pathol. 2010, 220:7-16.
35. Wolf B.B., Schuler M., Echeverri F., Green D.R. Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J. Biol. Chem. 1999, 274:30651-30656.
36. Yoon Y.S., Byun H.O., Cho H., et al. Complex II defect via down-regulation of iron-sulfur subunit induces mitochondrial dysfunction and cell cycle delay in iron chelation-induced senescence-associated growth arrest. J. Biol. Chem. 2003, 278:51577-51586.
37. Yoon Y.S., Cho H., Lee J.H., et al. Mitochondrial dysfunction via disruption of complex II activity during iron chelation-induced senescence-like growth arrest of Chang cells. Ann. N. Y. Acad. Sci. 2004, 1011:123-132.